Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy—A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin

SIMPLE SUMMARY: Currently, little is known about what therapeutic options exist for the treatment of metastatic urothelial carcinoma (mUC) after a therapy with checkpoint inhibitors (CPI). In the context of this systemic review, five therapy regimens tested in the post-CPI setting with adequate data...

Descripción completa

Detalles Bibliográficos
Autores principales: Deininger, Susanne, Törzsök, Peter, Oswald, David, Lusuardi, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268971/
https://www.ncbi.nlm.nih.gov/pubmed/34206980
http://dx.doi.org/10.3390/cancers13133206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268971/
https://www.ncbi.nlm.nih.gov/pubmed/34206980
http://dx.doi.org/10.3390/cancers13133206

Ejemplares similares